Literature DB >> 7013866

The choice of treatment for cancer patients based on covariate information.

D P Byar, S B Green.   

Abstract

This paper discusses the analysis of data from clinical trials in an effort to determine whether comparisons of treatment in various subsets of patients yield sufficiently different results to justify the idea that there may be an optimal treatment for each patient based on his individual characteristics. This approach belongs more to the field of exploratory data analysis than to classical hypothesis testing. The idea of treatment-covariate interactions is discussed and methods for detecting them are presented using parametric survival models incorporating covariate information. A detailed example using data from a clinical trial of estrogen treatment for prostatic cancer is presented. In this study significant treatment-covariate interactions were detected. Subsidiary analyses indicated that young patients with high grade tumors should have been treated with estrogens, but that older patients with low grade tumors were harmed by estrogen treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7013866

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  13 in total

1.  A causal framework for classical statistical estimands in failure-time settings with competing events.

Authors:  Jessica G Young; Mats J Stensrud; Eric J Tchetgen Tchetgen; Miguel A Hernán
Journal:  Stat Med       Date:  2020-01-27       Impact factor: 2.373

2.  Detecting moderator effects using subgroup analyses.

Authors:  Rui Wang; James H Ware
Journal:  Prev Sci       Date:  2013-04

3.  Estimating subject-specific dependent competing risk profile with censored event time observations.

Authors:  Yi Li; Lu Tian; Lee-Jen Wei
Journal:  Biometrics       Date:  2010-07-09       Impact factor: 2.571

4.  Detecting treatment-covariate interactions using permutation methods.

Authors:  Rui Wang; David A Schoenfeld; Bettina Hoeppner; A Eden Evins
Journal:  Stat Med       Date:  2015-03-02       Impact factor: 2.373

5.  NONPARAMETRIC ESTIMATION OF CONDITIONAL CUMULATIVE HAZARDS FOR MISSING POPULATION MARKS.

Authors:  Dipankar Bandyopadhyay; Amalia Jácome Pumar
Journal:  Aust N Z J Stat       Date:  2010       Impact factor: 0.640

6.  Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.

Authors:  B Fisher; C K Redmond; D L Wickerham; H E Rockette; A Brown; J Allegra; D Bowman; D Plotkin; J Wolter
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 7.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

8.  The extension of total gain (TG) statistic in survival models: properties and applications.

Authors:  Babak Choodari-Oskooei; Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2015-07-01       Impact factor: 4.615

9.  Correcting for misclassification and selection effects in estimating net survival in clinical trials.

Authors:  Juste Aristide Goungounga; Célia Touraine; Nathalie Grafféo; Roch Giorgi
Journal:  BMC Med Res Methodol       Date:  2019-05-16       Impact factor: 4.615

10.  Subgroup identification in clinical trials via the predicted individual treatment effect.

Authors:  Nicolás M Ballarini; Gerd K Rosenkranz; Thomas Jaki; Franz König; Martin Posch
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.